We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

82 hedge funds and large institutions have $29.7M invested in Outlook Therapeutics in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 8

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

9% more funds holding

Funds holding: 75 → 82 (+7)

0% more capital invested

Capital invested by funds: $29.6M → $29.7M (+$125K)

0.07% less ownership

Funds ownership: 0.61% → 0.53% (-0.07%)

Holders
82
Holders Change
+7
Holders Change %
+9.33%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
34
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.14M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$532K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$389K
4
Millennium Management
Millennium Management
New York
+$382K
5
Northern Trust
Northern Trust
Illinois
+$287K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$3.59M
2
GCP
GSA Capital Partners
United Kingdom
-$201K
3
Goldman Sachs
Goldman Sachs
New York
-$130K
4
VF
Vista Finance
Missouri
-$67.1K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$53.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$86.3K +$53K +2,370 +149%
AIG
27
American International Group
New York
$81.4K +$20.8K +930 +33%
Goldman Sachs
28
Goldman Sachs
New York
$77.4K -$130K -5,826 -62%
MCA
29
MSH Capital Advisors
Arizona
$74.3K +$76.3K +3,408 New
GCM
30
Gables Capital Management
Florida
$72.5K – – –
Squarepoint
31
Squarepoint
New York
$71K +$72.9K +3,257 New
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$70.7K +$53.2K +2,377 +274%
SG Americas Securities
33
SG Americas Securities
New York
$68K +$69.3K +3,097 New
VOYA Investment Management
34
VOYA Investment Management
Georgia
$66.2K +$15.4K +687 +29%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$62.7K +$11.4K +510 +22%
FCC
36
Flower City Capital
New York
$58.9K – – –
Envestnet Asset Management
37
Envestnet Asset Management
Illinois
$55.2K +$25.8K +1,154 +84%
PVAMC
38
PPS&V Asset Management Consultants
Michigan
$54.7K – – –
Corient Private Wealth
39
Corient Private Wealth
Florida
$53.4K +$22.4K +1,000 +69%
Invesco
40
Invesco
Georgia
$51.8K +$8.81K +394 +20%
AllianceBernstein
41
AllianceBernstein
Tennessee
$47.9K – – –
PAM
42
PVG Asset Management
Colorado
$46.1K +$28.9K +1,291 +157%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$39.2K – – –
FFN
44
Focus Financial Network
Minnesota
$37.3K +$38.3K +1,710 New
T. Rowe Price Associates
45
T. Rowe Price Associates
Maryland
$32K +$11.2K +499 +52%
TRCT
46
Tower Research Capital (TRC)
New York
$26K +$17.8K +796 +209%
Creative Planning
47
Creative Planning
Kansas
$25.1K – – –
OC
48
Oppenheimer & Co
New York
$24.9K +$559 +25 +2%
KW
49
KWB Wealth
California
$23.9K +$24.8K +1,108 New
Osaic Holdings
50
Osaic Holdings
Arizona
$23.9K +$7.18K +321 +41%
1
2
3 4

OTLK Hedge Fund Activity: Q1 2023 in Review

82 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2023, worth a combined $29.7M — up 0.42% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OTLK positions and 7 closed out — a net gain of 7 holders — while 34 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $1.14M. The largest seller was Altium Capital Management, exiting entirely with an estimated $3.59M sold.

  • 82 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2023, up from 75 in Q4 2022.
  • Funds reported $29.7M of Outlook Therapeutics stock for Q1 2023, up 0.42% quarter-over-quarter.
  • 14 funds opened new Outlook Therapeutics positions in Q1 2023 and 7 closed out, a net change of +7 holders.
  • The largest Outlook Therapeutics buyer in Q1 2023 was BlackRock, an estimated $1.14M added.
  • The largest Outlook Therapeutics seller in Q1 2023 was Altium Capital Management, an estimated $3.59M sold.

Based on aggregated 13F filings for Q1 2023.